CG
OREX

Cutler Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Cutler Group’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22,500
Closed -$29K – 7763
2017
Q1 		$29K Buy
+22,500
New +$88.8K ﹤0.01% 2972

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cutler Group's OREX Position: Q3 2017 in Review

Cutler Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2017, closing a stake of 3,637 shares — an estimated $10K sold.

Cutler Group first reported a position in OREX in Q1 2016 and held it in 6 quarters. The position peaked at $12K in Q1 2016. 42 funds tracked by Wall St. Rank hold OREX as of Q3 2017.

  • Cutler Group reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Cutler Group sold 3,637 Orexigen Therapeutics, Inc. shares in Q3 2017, an estimated $10K.
  • Cutler Group first reported a position in Orexigen Therapeutics, Inc. in Q1 2016 and held it in 6 quarters.
  • Cutler Group's Orexigen Therapeutics, Inc. position peaked at $12K in Q1 2016.
  • 42 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2017.

Based on Cutler Group's 13F filing for Q3 2017, filed 17 Oct 2017.